Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy
- 13 May 2019
- journal article
- research article
- Published by Wiley in Transplant Infectious Disease
- Vol. 21 (6) , e13106
Abstract
Introduction: The complex interaction between cytomegalovirus (CMV) infection and acute rejection after kidney transplantation is well recognized.Methods: This single center retrospective cohort analysis investigated the incidence and risk factors associated with CMV infection after treatment for acute rejection (tAR) in kidney transplant recipients receiving only CMV preemptive therapy. Of the 938 kidney transplants performed between 04/30/2014 and 04/30/2015 we identified 87 (9.3%) that were treated for acute rejection within the first year.Results: Most patients (64%) received rATG induction therapy followed by tacrolimus in combination with azathioprine (67%) or mycophenolate (33%) and corticosteroids. The incidence of CMV infection/disease after tAR was 47%, of which 73% occurred within 30 days. Using multivariable logistic regression analysis, eGFR at 1 month (OR = 0.98; 95% CI, 0.97‐0.99; P = 0.007) and timing of tAR (OR = 0.98; 95% CI, 0.96‐0.99; P = 0.021) were independently associated with CMV infection/disease after tAR.Conclusion: In this cohort of kidney transplant recipients receiving tacrolimus‐based immunosuppressive and preemptive CMV therapy, almost 50% developed CMV infection/disease after tARin the first year of transplantation. Early rejection and poor initial renal function were risk factors associated with CMV infection or disease.Keywords
This publication has 26 references indexed in Scilit:
- The current burden of cytomegalovirus infection in kidney transplant recipients receiving no pharmacological prophylaxisBrazilian Journal of Nephrology, 2017
- Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantationThe Brazilian Journal of Infectious Diseases, 2016
- Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverageClinical Transplantation, 2016
- Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus DosesAmerican Journal of Transplantation, 2015
- Cytomegalovirus infection after acute rejection therapy in seropositive kidney transplant recipientsTransplant Infectious Disease, 2014
- CMV: Prevention, Diagnosis and TherapyAmerican Journal of Transplantation, 2013
- Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients: 1-Year Results of a Randomized Clinical TrialTransplantation, 2012
- Acute rejection and graft survival in renal transplanted patients with viral diseasesLaboratory Investigation, 2004
- The Impact of Cytomegalovirus Infection and Disease on Rejection Episodes in Renal Allograft RecipientsAmerican Journal of Transplantation, 2002
- Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analysesTransplant International, 2000